We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
COMPASS Pathways has received approval from the US Food and Drug Administration (FDA) for a clinical trial in psilocybin therapy for treatment-resistant depression. Regulatory approvals for the trial have already been given in the UK, the Netherlands and